Lars Wilde

Lars Wilde is Chairman, CEO and co-founder of Pangea Bio. He is a serial entrepreneur across healthcare, tech and biotech, and an active angel and venture investor as well as active board member through his private investment firm, Wilde Ventures.

He is also Chairman and co-founder of Kadence Bio, a Phase 2 biotech developing an on-demand treatment for premature ejaculation.

Previously, Lars co-founded COMPASS Pathways (Nasdaq: CMPS), a mental health biotech advancing evidence-based psychedelic therapies. As President, COO and CBO, he helped scale COMPASS into Phase 3 clinical development for psilocybin therapy in treatment-resistant depression, which successfully completed Phase 3 clinical trials.

Lars also co-founded AtaiBeckley (Nasdaq: ATAI), a biopharmaceutical company developing an array of psychedelic therapies across mood and addiction disorders, with multiple programs in Phase 2 and Phase 3 clinical trials.

Across COMPASS and atai, Lars contributed to two NASDAQ IPOs and helped raise over USD 1 billion in capital.

Earlier in his career, Lars founded and led Burnhard / Springlane, a leading European direct-to-consumer kitchen and BBQ company, and co-founded Pakama Athletics and Otto Wilde Grillers. He previously worked as an investor at Waterland Private Equity, where he supported buy-and-build strategies including launching VivaNeo, a leading European IVF group, today TFP Fertility.

Lars holds a Master’s in Finance from IE Business School and a BSc in Business Administration from Rotterdam School of Management, Erasmus University, with exchange semesters at Copenhagen Business School and the Ross School of Business (University of Michigan).

‍